Additional Study Information: This study aims to collect information about the symptoms and treatments of patients who have severely clogged arteries and are treated with commercially available Boston Scientific Corporation drug-eluting devices marketed for the treatment of lesions located in the peripheral vasculature. Participation in the study is expected to last for up to two (2). If you choose to be part of this research, we will ask you to be involved in routine follow-up visits at 6 months, 1 year, and every year thereafter for up to 2 years. Additionally, you may be asked to complete a survey before being treated with the device(s) and a survey at 30 days, 6 months, and 12 months after the procedure to collect your treatment preferences and experiences. There are no or minimal risks from participating in this study. There are no physical risks associated with this study. We will take measures to maintain the confidentiality of all study participants, however, accidental disclosure of your medical information is a potential risk. The study may have no benefits to you directly. You have the alternative of not taking part in this study.